Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-06-04
- Target Recruit Count
- 42
- Registration Number
- NCT06440993
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
🇩🇪Universitätsklinikum Düsseldorf, Düsseldorf, Germany
🇩🇪Universitätsklinikum Köln, Köln, Germany
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
- Conditions
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 129
- Registration Number
- NCT06431633
- Locations
- 🇪🇸
Hospital General de Elche, Elche, Alicante, Spain
🇪🇸ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.
- Conditions
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT06426056
Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 37
- Registration Number
- NCT06422858
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Emory University
- Target Recruit Count
- 44
- Registration Number
- NCT06423326
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Serplulimab Plus Chemoradiotherapy for Stage III-IVA Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Target Recruit Count
- 240
- Registration Number
- NCT06419673
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT06417814
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT06406465
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Target Recruit Count
- 40
- Registration Number
- NCT06387056
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Francesco De Cobelli
- Target Recruit Count
- 33
- Registration Number
- NCT06375915
- Locations
- 🇮🇹
Department of Radiology, IRCCS Ospedale San Raffaele, Milano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.